Trial Profile
Drug survival and clinical outcomes in rheumatoid arthritis (RA) patients after a non-medical switch from the originator to biosimilar Etanercept (SB4)- a Norwegian Multicenter Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2019
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 15 Jun 2019 Preliminary results (2 years) presented at the 20th Annual Congress of the European League Against Rheumatism
- 13 Jul 2018 New trial record
- 16 Jun 2018 Preliminary results (n=191, Since Apr 2016, data retrieved from compuer system 21 Jan 2018) presented at the 19th Annual Congress of the European League Against Rheumatism